skip to Main Content

Randomized Controlled Trial Validates Effectiveness of the AllazoHealth AI Engine

AllazoHealth and Large Regional Payer Validate Use of Artificial Intelligence in Improving Medication Adherence with Randomized Controlled Study

PRESS RELEASE, October 30, 2017 — AllazoHealth has co-published a randomized controlled study with Blue Cross Blue Shield of North Carolina. The study titled, “Improving Medication Adherence by Better Targeting Interventions Using Artificial Intelligence – a Randomized Controlled Trial”, was conducted for the health plan’s Medicare Advantage Part D (MAPD) population of 104,392 patients. The main objective was to improve adherence rates across the three groupings of medication classes that are directly tied to end-of-year Star Ratings and bonus payments: renin angiotensin system antagonists (RASAs), oral anti-diabetics (OADs), and statins.

Read the full press release here

Download the study here